Gabapentin Enacarbil

Introduction Overview

Generic Name

gabapentin enacarbil

Brand Name

Horizant

Dosage Form

Extended-release tablet

Drug Class

Gamma-aminobutyric acid analogs

Pharmacokinetics

Absorption:
Gabapentin enacarbil is an L-prodrug of gabapentin designed for improved oral bioavailability compared to gabapentin itself. Upon oral administration, gabapentin enacarbil undergoes enzymatic hydrolysis by nonspecific esterases in the intestinal wall and liver, which releases active gabapentin. This prodrug formulation allows for more consistent and sustained absorption throughout the gastrointestinal tract, especially in the proximal and distal regions, overcoming the saturable absorption limitations observed with gabapentin. The extended-release tablet formulation further provides controlled release to maintain steady plasma concentrations. Food intake enhances absorption, and the medication should be taken with food to optimize bioavailability.

Distribution:
After absorption, gabapentin, the active moiety, is distributed widely throughout the body. Gabapentin is not extensively bound to plasma proteins, typically less than 3%, facilitating free distribution into tissues. It crosses the blood-brain barrier via the L-type large neutral amino acid transporter and accumulates preferentially in nervous system tissues, where it exerts its pharmacologic effects. The volume of distribution of gabapentin is approximately 58 liters in adults, reflecting substantial tissue uptake. There is minimal binding to any particular tissue proteins, and no accumulation in fatty tissue has been reported.

Metabolism:
Gabapentin enacarbil is rapidly and extensively metabolized to gabapentin via enzymatic hydrolysis by nonspecific esterases predominantly in the enterocytes of the gastrointestinal tract. Subsequent metabolism of gabapentin itself is minimal; gabapentin is not significantly metabolized by hepatic cytochrome P450 enzymes and thus possesses a low potential for cytochrome-mediated drug interactions. The parent prodrug is not detected in systemic circulation, reflecting complete conversion to gabapentin prior to systemic exposure.

Elimination:
Gabapentin is eliminated primarily by renal excretion as unchanged drug. Approximately 80–90% of an administered dose is excreted unchanged in urine. The elimination half-life of gabapentin ranges from 5 to 7 hours in individuals with normal renal function but is prolonged in patients with renal impairment. Because elimination is predominantly renal, dose adjustments are recommended in patients with impaired kidney function to prevent drug accumulation. Gabapentin is not significantly cleared by hepatic metabolism or biliary excretion.

Dosage Forms

Available Dosage Forms:
Gabapentin enacarbil is available exclusively as extended-release tablets for oral administration. The tablet formulation is designed to provide a controlled release of the drug over time, enabling consistent plasma levels and convenient once or twice daily dosing.

Dosages for Adults and Adolescents:
- For Restless Legs Syndrome (RLS):
- Adults: A single dose of 600 mg taken orally once daily at approximately 5 PM. Dose adjustments may be made by the prescribing physician according to patient response and tolerability.
- Children and adolescents: Safety and efficacy have not been established; dosing must be determined by a specialist if used.
- For Postherpetic Neuralgia (PHN):
- Adults: Initial dosing is 600 mg orally once daily in the morning for the first 3 days to establish tolerance. After day three, the dose is typically increased to 600 mg twice daily (morning and evening). The maximum recommended dose is generally 1,200 mg per day, divided into two doses.
- Children and adolescents: Dosing is not established and should be determined by the healthcare provider.

Specific Patient Populations:
- Geriatric patients: No geriatric-specific dosing modifications have been established; however, due to higher likelihood of age-related renal impairment, dose adjustments based on renal function are recommended.
- Renal impairment: Dose adjustments are necessary as the drug is renally excreted, to avoid accumulation and toxicity.
- Pediatric patients: Safety and efficacy not established; use is not routinely recommended without specialist guidance.
- Patients required to sleep during daytime and remain awake at night: Use is not recommended for those with this sleep pattern, such as shift workers, due to the drug's influence on sleep-wake cycles.

Note: The extended-release tablets should be swallowed whole with food; tablets must not be crushed, chewed, or broken as this may impair the slow-release mechanism and alter pharmacokinetics.

Mechanism Of Action

Gabapentin enacarbil functions as a prodrug that is converted after absorption into gabapentin, which is the active compound responsible for its pharmacological effects. Gabapentin itself is a structural analogue of gamma-aminobutyric acid (GABA), although it does not directly bind to GABA receptors or influence GABA synthesis or uptake. Instead, its therapeutic actions are mediated primarily through interaction with specific voltage-gated calcium channels.

At the molecular level, gabapentin binds with high affinity to the alpha-2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system. Binding to this auxiliary subunit decreases calcium influx into neurons, particularly in the dorsal horn of the spinal cord and other central nervous system areas involved in nociception and sensory processing. This modulation reduces the release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, which contribute to pain transmission and abnormal sensory signaling associated with neuropathic pain and restless legs syndrome.

The reduction of excitatory neurotransmitter release leads to decreased neuronal excitability and attenuation of pathological neuronal hyperactivity associated with neuropathic conditions and sensory disturbances. Clinical implication of these effects includes the alleviation of symptoms such as discomfort and the urge to move in restless legs syndrome, and reduction of neuropathic pain in postherpetic neuralgia.

Compared to other gabapentinoids, gabapentin enacarbil’s prodrug formulation allows for improved bioavailability and consistent plasma concentrations, potentially offering enhanced clinical efficacy and more stable symptom control. Research studies have demonstrated the drug’s effectiveness in reducing RLS symptoms and postherpetic neuralgia pain with a tolerable safety profile, which can be partially attributed to its steady pharmacokinetic profile.

Pharmacological Actions

Modulates voltage-gated calcium channels by binding to the alpha-2-delta subunit, reducing calcium influx in presynaptic neurons.
Decreases release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P, attenuating neuronal hyperexcitability.
Exerts analgesic effects in neuropathic pain conditions by reducing abnormal neuronal firing and excitatory signaling.
Alleviates sensory disturbances and motor restlessness in Restless Legs Syndrome by modulating central nervous system sensory pathways.
Improves sleep quality in patients with RLS through symptom control, indirectly impacting sleep architecture.
Does not directly bind to GABA receptors or alter GABA synthesis, distinguishing it mechanistically from typical GABAergic agents.
Displays extended-release pharmacokinetics, resulting in sustained therapeutic plasma concentrations.
Exhibits minimal hepatic metabolism, reducing potential for drug-drug interactions mediated by cytochrome P450 enzymes.
Provides better oral bioavailability than gabapentin due to its prodrug design, allowing more consistent systemic exposure.
Demonstrates dose-dependent pharmacokinetics influenced by renal function, requiring dose adjustments in renal impairment.
Has potential CNS depressant properties, which may contribute to side effects such as drowsiness and dizziness.
Possesses a relatively low potential for abuse and dependence compared to other CNS-acting drugs.
Demonstrates efficacy in both neuropathic pain and movement disorder symptomatology through central nervous system modulation.

Therapeutic Or Clinical Uses

Treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) to reduce uncomfortable sensations and motor restlessness.
Management of postherpetic neuralgia (PHN), providing analgesia for neuropathic pain following shingles infection.
Improvement of sleep quality in patients with RLS by alleviating leg discomfort that interferes with sleep onset and maintenance.
Adjunctive therapy in neuropathic pain syndromes where standard analgesics are ineffective or poorly tolerated.
Potential off-label use in other neuropathic pain conditions, although primarily approved for PHN and RLS.
Reduction of sensory nerve hyperexcitability symptoms associated with certain neurologic disorders.
As a safer alternative to immediate-release gabapentin formulations due to its extended-release profile ensuring better compliance.
Use in adult patients requiring long-term management of neuropathic symptoms with stable plasma drug levels.
Therapeutic option suitable for patients who have difficulty tolerating gabapentin’s variable absorption profile.
Contributes to improved quality of life in patients with chronic neuropathic pain and movement disorders by symptom control.
Recommended only with prescription and under medical supervision to manage dose titration and monitor adverse effects.
Not established for pediatric populations; use limited to adult patients based on clinical trial data.
Therapeutic dosing adjusted for renal function to prevent toxicity and maintain efficacy.

Side Or Adverse Effects

Dizziness and drowsiness, common CNS effects that may impair ability to operate machinery or drive.
Tiredness and fatigue resulting from central nervous system depressant effects.
Swelling or bloating of face, limbs, or other extremities due to fluid retention.
Irritability, feelings of sadness or discouragement, which may indicate mood alterations.
Tingling or numbness in the hands or feet (paresthesia).
Loss of appetite and rapid weight gain noted in some users.
Trouble concentrating or cognitive impairment during therapy.
Unusual behavioral changes including agitation, nervousness, or depression.
Serious allergic reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), characterized by rash, fever, swollen lymph nodes.
Respiratory depression especially when combined with opioid analgesics or other CNS depressants.
Gastrointestinal disturbances including nausea, vomiting, and dry mouth.
Blurred vision and dizziness reported less frequently.
Sexual dysfunction such as decreased libido or erectile dysfunction.
Rare occurrences of confusion, fainting, fast heartbeat, or chest discomfort.
Potential for suicidal thoughts or tendencies requiring careful monitoring during treatment.

Precautions

Monitor for CNS depression symptoms before engaging in activities requiring alertness.
Patients with history of depression or mood disorders should be closely observed for worsening symptoms or suicidal ideation.
Use caution in patients with renal impairment; dose adjustment is necessary due to renal elimination.
Do not discontinue treatment abruptly to avoid precipitating seizures or withdrawal symptoms; taper dose gradually under medical supervision.
Avoid concurrent use with CNS depressants and opioids unless closely supervised due to respiratory depression risk.
Not recommended for patients required to sleep during daytime and remain awake at night, such as shift workers.
Women who are breastfeeding should weigh potential benefits against unknown infant risks before use.
Inform healthcare providers about all concomitant medications to assess for interactions.
Watch for signs of serious allergic reaction and discontinue drug if symptoms such as rash or swollen glands occur.
Use with caution in elderly patients given potential for age-related renal dysfunction and increased side effect susceptibility.
Avoid alcohol consumption during treatment to reduce additive CNS depression.
Regular follow-up visits are essential to monitor therapeutic response and adverse effects.
Use in pediatric population has not been established, necessitating specialist oversight.
Patients should be counseled regarding side effects and instructed to report new or worsening symptoms promptly.
Store medication properly to maintain drug stability; keep out of reach of children.

Warnings

Risk of respiratory depression when combined with narcotic pain medicines or other CNS depressants.
Potential for serious and life-threatening hypersensitivity reactions including DRESS syndrome.
May cause dizziness, somnolence, and impaired concentration, increasing risk of accidents.
Warnings of suicidal ideation and behavioral changes; monitor patients for new or worsening depression.
Do not abruptly discontinue medication to prevent seizure risk.
Not recommended for use in patients with the need to sleep in the daytime due to risk of sedation.
Use with caution in patients with pulmonary disease or compromised respiratory function.
Potential for drug interactions that may increase side effects or reduce effectiveness.
Dose adjustments necessary in renal impairment to prevent toxicity.
Avoid use during breastfeeding unless clearly justified by potential benefits outweighing risks.
May cause weight gain which can have long-term health impacts if unmonitored.
Use caution when prescribing to elderly; increased risk of sedation and falls.
Sedation may impair mental or physical abilities required for safe operation of machinery or driving.
Inform patients about storage and safe disposal to prevent accidental ingestion.
Pregnancy category and safety have not been well established; use only if clearly needed.

Contraindication

Known hypersensitivity to gabapentin enacarbil or any of its excipients.
Patients with history of severe allergic reactions to gabapentinoids.
Concomitant use with gabapentin may need special consideration or be contraindicated.
Use is contraindicated in patients who need to sleep during daytime and be awake at night (e.g., shift workers).
Patients with severe respiratory depression unless closely monitored.
Should not be used in pediatric patients due to lack of established safety and efficacy.
Avoid in individuals with known allergy to gamma-aminobutyric acid analogs.
Contraindicated if active severe dermatologic reactions consistent with DRESS have occurred.
Patients with acute intoxication of alcohol, sedatives, or hypnotics should avoid use until clearance.
Use contraindicated in patients with history of significant CNS depression from similar agents.
Not recommended in patients unable to swallow tablets intact, due to extended-release formulation.
Patients with severe renal impairment require dose adjustments but absolute contraindication depends on clinical scenario.

Drug Interactions

Potentiation of CNS depressant effects when used with opioids, benzodiazepines, barbiturates, and other sedatives.
Concomitant administration with other gabapentinoids such as gabapentin or pregabalin may increase additive effects and side effects.
Antacids containing magnesium or aluminum may reduce absorption if administered simultaneously; separate administration by at least 2 hours.
Potential interaction with alcohol increasing sedation, dizziness, and risk of respiratory depression.
Co-administration with muscle relaxants like baclofen may enhance neuromuscular side effects.
May interact with several psychoactive medications including antipsychotics (e.g., aripiprazole, clozapine) increasing sedation or other CNS effects.
Drugs affecting renal function can alter elimination of gabapentin requiring dose adjustments.
Interactions with calcium channel blockers have been reported but clinical significance is unclear.
May increase the sedative effects of antihistamines such as diphenhydramine or hydroxyzine.
Interactions with other CNS agents such as zolpidem or eszopiclone increase risk of sedation.
Use with caution alongside narcotics fentanyl, morphine, hydrocodone due to enhanced respiratory depression risk.
Certain anesthetics and analgesics (e.g., ketamine, dexmedetomidine) may interact at CNS level.
Concomitant use with cannabis or cannabidiol may enhance CNS effects necessitating monitoring.
Pharmacokinetics not significantly affected by cytochrome P450 inducers or inhibitors, reducing risk of metabolic drug interactions.
Some drug classes like magnesium-containing antacids must be timed appropriately to avoid absorption interference.

Preparations Of The Drug

Extended-release oral tablets containing 600 mg of gabapentin enacarbil.
Tablets formulated for once or twice daily dosing with release properties to maintain steady plasma levels.
Packaged in blister packs or bottles, labeled with dosing instructions specifying administration with food.
No immediate-release formulations are available commercially for this prodrug.
Brand name preparation is 'Horizant', the only marketed form currently approved by regulators.
Manufactured under Good Manufacturing Practices ensuring consistent bioavailability and stability.
Prepared to be taken intact; tablets should not be crushed, broken, or chewed to preserve extended-release characteristics.
Packaging includes patient Medication Guide outlining proper use, storage, and side effect information.
Stored at controlled room temperature conditions, protected from moisture and light.
Available only by prescription to ensure appropriate indication and dosing management.
Labeling includes warnings about potential CNS depression and drug interactions.
Supplied in unit dose to facilitate correct dosing adherence.
Includes tamper-evident packaging to ensure integrity up to point of use.
Formulations do not contain lactose, gluten, or common allergens, minimizing hypersensitivity risk.
No parenteral or alternative dosage forms such as injections or suspensions are currently available.